Table 1 Baseline and clinical characteristics of the study cohort.

From: Change in platelet and leukocyte counts and hospital mortality in adults with acute kidney injury receiving continuous renal replacement therapy

Variables

Overall

(n = 1413)

Survived

(n = 660)

Died

(n = 753)

P value

Age, mean years (SD)

56.32 (14.71)

54.23 (14.99)

58.10 (14.24)

< 0.001

Men, n (%)

895 (63.3)

418 (63.3)

477 (63.3)

1.000

Race, n (%)

   

0.662

 White

1166 (82.5)

551 (83.5)

615 (81.7)

 

 Black

155 (11.0)

69 (10.5)

86 (11.4)

 

 Other

92 (6.5)

52 (6.9)

40 (6.1)

 

Study site

    

 UK

999 (70.7)

466 (70.6)

533 (70.8)

0.988

 UTSW

414 (29.3)

194 (29.4)

220 (29.2)

 

 Weight, kg, mean (SD)

95.71 (31.33)

93.76 (28.38)

97.39 (33.60)

0.037

 Baseline Serum Creatinine, mean (SD)

1.74 (1.77)

1.90 (2.08)

1.60 (1.40)

0.005

 Charlson Comorbidity Index, mean (SD)

4.27 (2.64)

4.05 (2.67)

4.45 (2.61)

0.005

 Mechanical ventilation, n (%)

1280 (90.6)

585 (88.6)

695 (92.3)

0.024

 SOFA at ICU admission, mean (SD)

9.55 (4.98)

8.83 (4.99)

10.16 (4.90)

< 0.001

 SOFA at CRRT initiation, mean (SD)

12.73 (4.81)

11.73 (5.00)

13.58 (4.48)

< 0.001

 Hospital LOS, mean days (SD)

26.63 (25.83)

35.94 (30.41)

18.67 (17.61)

< 0.001

 ICU LOS, mean days (SD)

17.22 (18.64)

20.43 (22.62)

14.44 (13.75)

< 0.001

 Time from ICU admission to CRRT initiation, mean days (SD)

5.36 (8.91)

5.07 (9.26)

5.62 (8.57)

0.250

 CRRT duration, mean days (SD)

7.57 (9.46)

7.54 (9.65)

7.60 (9.30)

0.894

 Platelets before CRRT, a x 109/L, mean (SD)

159.04 (103.78)

166.25 (109.60)

152.69 (98.00)

0.014

 Platelets during CRRT, a x 109/L, mean (SD)

122.19 (86.74)

131.93 (88.62)

113.60 (84.19)

< 0.001

 % Drop in platelets during CRRT, b x 109/L, mean (SD)

14.02 (47.52)

10.06 (50.57)

17.52 (44.39)

0.003

% Drop in platelets during CRRT, b, c SD groups, n (%)

   

0.019

 < -1 SD (<-33.49%)

164 (11.6)

90 (13.6)

74 (9.8)

 

 ± 1 SD (-33.49–61.54%)

1111 (78.6)

517(78.3)

594 (78.9)

 

 > 1 SD (> 61.54%)

131 (9.3)

52 (7.9)

79 (10.5)

 

 WBC before CRRT, a x 109/L, mean (SD)

14.46 (12.41)

13.99 (10.91)

14.85 (13.55)

0.199

 WBC during CRRT, a x 109/L, mean (SD)

16.71 (11.20)

15.27 (10.92)

17.93 (11.29)

< 0.001

 % Rise in WBC during CRRT, d x 109/L, mean (SD)

38.15 (97.30)

30.31 (94.80)

44.83 (98.95)

0.005

% Rise in WBC during CRRT, c, d SD groups, n (%)

   

< 0.001

 < -1 SDs (<-59.15%)

26 (1.8)

11 (1.7)

15 (2.0)

 

 ± 1 SD (-59.15–135.45%)

1259 (89.1)

594 (90.0)

665 (88.3)

 

 > 1 SDs (> 135.45%)

110 (7.8)

37 (5.6)

73 (9.7)

 
  1. Footnote: SD: standard deviation; UK: University of Kentucky; UTSW: University of Texas Southwestern, SOFA: sequential organ failure assessment, ICU: intensive care unit, CRRT: Continuous renal replacement therapy, LOS: length of stay.
  2. a Mean of platelets and mean of WBCs was calculated by averaging data from 7 days before or 7 days after CRRT initiation.
  3. b % drop in platelets = (mean of platelets before CRRT-mean of platelets after CRRT)/(mean of platelets before CRRT)*100%. A positive value indicated a drop in platelets after CRRT initiation; a negative value indicated a rise in platelets after CRRT initiation. Seven patients had missing platelet data either before or after CRRT and were not included in the analysis.
  4. c 7 patients (1 survived and 6 died) had no data of platelet/WBC counts before or after CRRT.
  5. d % rise in WBCs = (mean of WBCs after CRRT-mean of WBCs before CRRT)/(mean of WBCs before CRRT)*100%. A positive value indicated a rise in WBCs after CRRT initiation; a negative value indicated a drop in platelets after CRRT initiation. Eighteen patients had missing WBC data either before or after CRRT and were not included in the analysis.
Back to article page